

# BPR evaluation - Public consultation

Fields marked with \* are mandatory.

## Introduction

---

## About you

---

### \* Language of my contribution

- Bulgarian
- Croatian
- Czech
- Danish
- Dutch
- English
- Estonian
- Finnish
- French
- German
- Greek
- Hungarian
- Irish
- Italian
- Latvian
- Lithuanian
- Maltese
- Polish
- Portuguese
- Romanian

- Slovak
- Slovenian
- Spanish
- Swedish

\* I am giving my contribution as

- Academic/research institution
- Business association
- Company/business
- Consumer organisation
- EU citizen
- Environmental organisation
- Non-EU citizen
- Non-governmental organisation (NGO)
- Public authority
- Trade union
- Other

\* First name

Denisa

\* Surname

Klieštíková

\* Email (this won't be published)

kliestikova@komora.cz

\* Country of origin

Please add your country of origin, or that of your organisation.

*This list does not represent the official position of the European institutions with regard to the legal status or policy of the entities mentioned. It is a harmonisation of often divergent lists and practices.*

Afghanistan

Djibouti

Libya

Saint Martin

• Åland Islands	• Dominica	• Liechtenstein	• Saint Pierre and Miquelon
• Albania	• Dominican Republic	• Lithuania	• Saint Vincent and the Grenadines
• Algeria	• Ecuador	• Luxembourg	• Samoa
• American Samoa	• Egypt	• Macau	• San Marino
• Andorra	• El Salvador	• Madagascar	• São Tomé and Príncipe
• Angola	• Equatorial Guinea	• Malawi	• Saudi Arabia
• Anguilla	• Eritrea	• Malaysia	• Senegal
• Antarctica	• Estonia	• Maldives	• Serbia
• Antigua and Barbuda	• Eswatini	• Mali	• Seychelles
• Argentina	• Ethiopia	• Malta	• Sierra Leone
• Armenia	• Falkland Islands	• Marshall Islands	• Singapore
• Aruba	• Faroe Islands	• Martinique	• Sint Maarten
• Australia	• Fiji	• Mauritania	• Slovakia
• Austria	• Finland	• Mauritius	• Slovenia
• Azerbaijan	• France	• Mayotte	• Solomon Islands
• Bahamas	• French Guiana	• Mexico	• Somalia
• Bahrain	• French Polynesia	• Micronesia	• South Africa
• Bangladesh	• French Southern and Antarctic Lands	• Moldova	• South Georgia and the South Sandwich Islands
• Barbados	• Gabon	• Monaco	• South Korea
• Belarus	• Georgia	• Mongolia	• South Sudan
• Belgium	• Germany	• Montenegro	• Spain
• Belize	• Ghana	•Montserrat	• Sri Lanka
• Benin	• Gibraltar	• Morocco	• Sudan
• Bermuda	• Greece	• Mozambique	• Suriname

● Bhutan	● Greenland	● Myanmar/Burma	● Svalbard and Jan Mayen
● Bolivia	● Grenada	● Namibia	● Sweden
● Bonaire Saint Eustatius and Saba	● Guadeloupe	● Nauru	● Switzerland
● Bosnia and Herzegovina	● Guam	● Nepal	● Syria
● Botswana	● Guatemala	● Netherlands	● Taiwan
● Bouvet Island	● Guernsey	● New Caledonia	● Tajikistan
● Brazil	● Guinea	● New Zealand	● Tanzania
● British Indian Ocean Territory	● Guinea-Bissau	● Nicaragua	● Thailand
● British Virgin Islands	● Guyana	● Niger	● The Gambia
● Brunei	● Haiti	● Nigeria	● Timor-Leste
● Bulgaria	● Heard Island and McDonald Islands	● Niue	● Togo
● Burkina Faso	● Honduras	● Norfolk Island	● Tokelau
● Burundi	● Hong Kong	● Northern Mariana Islands	● Tonga
● Cambodia	● Hungary	● North Korea	● Trinidad and Tobago
● Cameroon	● Iceland	● North Macedonia	● Tunisia
● Canada	● India	● Norway	● Türkiye
● Cape Verde	● Indonesia	● Oman	● Turkmenistan
● Cayman Islands	● Iran	● Pakistan	● Turks and Caicos Islands
● Central African Republic	● Iraq	● Palau	● Tuvalu
● Chad	● Ireland	● Palestine	● Uganda
● Chile	● Isle of Man	● Panama	● Ukraine

- China
- Israel
- Papua New Guinea
- United Arab Emirates
- Christmas Island
- Italy
- Paraguay
- United Kingdom
- Clipperton
- Jamaica
- Peru
- United States
- Cocos (Keeling) Islands
- Japan
- Philippines
- United States Minor Outlying Islands
- Colombia
- Jersey
- Pitcairn Islands
- Uruguay
- Comoros
- Jordan
- Poland
- US Virgin Islands
- Congo
- Kazakhstan
- Portugal
- Uzbekistan
- Cook Islands
- Kenya
- Puerto Rico
- Vanuatu
- Costa Rica
- Kiribati
- Qatar
- Vatican City
- Côte d'Ivoire
- Kosovo
- Réunion
- Venezuela
- Croatia
- Kuwait
- Romania
- Vietnam
- Cuba
- Kyrgyzstan
- Russia
- Wallis and Futuna
- Curaçao
- Laos
- Rwanda
- Western Sahara
- Cyprus
- Latvia
- Saint Barthélemy
- Yemen
- Czechia
- Lebanon
- Saint Helena
- Ascension and Tristan da Cunha
- Saint Helena
- Lesotho
- Saint Kitts and Nevis
- Zimbabwe
- Democratic Republic of the Congo
- Liberia
- Saint Lucia

The Commission will publish all contributions to this public consultation. You can choose whether you would prefer to have your details published or to remain anonymous when your contribution is published. **For the purpose of transparency, the type of respondent (for example, 'business association', 'consumer association', 'EU citizen') country of origin, organisation name and size, and its transparency register number, are always published. Your e-mail address will never be published.** Opt in to select the privacy option that best suits you. Privacy options default based on the type of respondent selected

I agree with the [personal data protection provisions](#)

## Introduction

Biocidal products (biocides) help to control unwanted organisms that are harmful to human or animal health or to the environment, or that cause damage to materials or human activities. These organisms include pests (insects, rats, mice) and microorganisms (bacteria, viruses, mould).

There are four main groups of biocidal products.

1. Disinfectants: disinfectants for human hygiene (hand disinfectants), general disinfectants (for the home, for food processing areas), drinking water disinfectants.
2. Preservatives: in-can preservatives to prevent the degradation of products / materials by bacteria / fungi in paints, detergents, wood, leather, cutting fluids, cooling tower disinfectants.
3. Pest control products: rodenticides, insecticides, repellents/attractants (mosquito spray).
4. Other biocidal products: anti-fouling paints on boats, embalming and taxidermist fluids.

Biocidal products can pose risks to humans, animals and the environment due to their properties and associated use patterns. Therefore, [Regulation \(EU\) No 528/2012](#) on biocidal products (Biocidal Products Regulation) governs the making available on the market and use of biocidal products to ensure that they do not result in harmful effects on human or animal health or unacceptable effects on the environment. It maintains the main principles of its predecessor, Directive 98/8/EC, while introducing some additional elements. The Biocidal Products Regulation entered into application on 1 September 2013.

The Biocidal Products Regulation sets the rules for the making available on the market and use of biocidal products and articles treated with such products. It aims to improve the functioning of the internal market for biocidal products while ensuring a high level of protection of human and animal health and the environment.

A [Report on the implementation of the Biocidal Products Regulation](#), adopted by the Commission in June 2021, identified some issues that hinder the proper functioning of the rules. These issues include:

- consistently long delays in both active substance approval and product authorisation processes;
- limited innovation for new biocidal active substances.

The report announced that an evaluation of the Biocidal Products Regulation will take place in 2025. The aim of the evaluation is to assess if the current rules are fit for purpose.

This public consultation will gather evidence from both stakeholders and the public. The findings of the consultation will inform the evaluation process.

More information on the Biocidal Products Regulation can be found on the [Commission's website](#).

### • Public consultation

The public consultation gives stakeholders the opportunity to share their views on:

- how to tackle current and future needs;
- whether the rules have contributed to its objectives of improving the functioning of the internal market for biocidal products and ensuring a high level of protection of human health, animal health and the environment;
- the benefits, problems, costs and challenges faced during its implementation.

Respondents are also invited to identify areas for improvement, simplification and cost-savings.

#### • **Instructions**

The first section of the questionnaire contains questions about you or the organisation you represent.

The questionnaire is split into a set of general questions for non-experts that require no or little knowledge of the Biocidal Products Regulation, and an additional set of questions targeting experts with good or excellent knowledge of the rules.

Where possible, you should include data and sources of information or practical examples to support your replies.

The questionnaire is available in all EU official languages (and you can reply in any EU official language). You can pause at any time and continue later. You can also download your contribution once you have submitted your answers.

### **QUESTIONNAIRE NON-EXPERTS**

#### **Question 1**

Did you know that biocidal products are regulated and authorised in the EU?

Yes  
 No

#### **Question 2**

Did you know that biocidal products undergo a thorough risk assessment before being placed on the market?

Yes  
 No

#### **Question 3**

Do you believe that biocidal products are necessary to control organisms harmful to human or animal health or to materials and human activities?

Yes

No

#### **Question 4**

Do you think that it is important to have EU rules in place to ensure the safe use of biocidal products, like disinfectants, preservatives and pest control products?

- Very important
- Important
- Neutral
- Not important
- Don't know

#### **Question 5**

Do you feel well informed about the approval decisions on biocidal active substances and authorisations or derogations concerning biocidal products?

- Yes
- No

#### **Question 6**

Do you know that there are public information websites, like [Information on biocides - ECHA, Overview - European Commission](#)?

- Yes
- No

#### **Question 7**

Do you purchase biocidal products like disinfectants or insecticides for home use?

- Yes
- No

#### **Question 8**

Do you use biocidal products in your professional life?

- Yes
- No

## Question 9

You can give more relevant information here

2500 character(s) maximum

You can upload a concise document, such as evidence to support your responses or a position paper.

Uploaded documents will be published alongside your questionnaire response, serving as supporting material to better understand your position. Although uploading documents is optional, it can provide us with valuable background information.

Only files of the type pdf,txt,doc,docx,odt,rtf are allowed

## QUESTIONNAIRE EXPERTS

**Evaluation criterion: EFFECTIVENESS (to what extent has the Biocidal Products Regulation achieved its intended objectives?)**

### Question 1

Have the following processes/requirements been effective in ensuring a high level of protection of human health, animal health and the environment?

	Very effective	Effective	Ineffective	Very ineffective	Don't know
Review programme to review the safety and efficacy of all existing biocidal active substances	<input type="radio"/>				
Approval of new active substances	<input type="radio"/>				
Exclusion and substitution criteria and rules for products containing substances meeting these criteria (including comparative assessment)	<input type="radio"/>				
Early review of an active substance approval	<input type="radio"/>				
Inclusion of in-situ products within the scope of the Biocidal Products Regulation	<input type="radio"/>				
Labelling requirements	<input type="radio"/>				
Data requirements for active substance approval	<input type="radio"/>				

## Question 2

How effective were the following processes/concepts/rules in improving the functioning of the internal market?

	Very effective	Effective	Ineffective	Very ineffective	Don't know
Review programme to review the safety and efficacy of all existing biocidal active substances	<input type="radio"/>				
Approval of new active substances	<input type="radio"/>				
Exclusion and substitution criteria and rules for products containing substances meeting these criteria, including comparative assessment	<input type="radio"/>				
Early review of active substance approval	<input type="radio"/>				
Annex I active substances /Simplified procedure for product authorisation	<input type="radio"/>				
Same biocidal products	<input type="radio"/>				
Biocidal products families	<input type="radio"/>				
Inclusion of in-situ products within the scope of the Biocidal Products Regulation	<input type="radio"/>				
National authorisation of biocidal products /renewals	<input type="radio"/>				
Mutual recognition of national authorisations /renewals	<input type="radio"/>				
Union authorisations/renewals	<input type="radio"/>				
Parallel trade permits	<input type="radio"/>				
Rules for treated articles	<input type="radio"/>				
Labelling requirements	<input type="radio"/>				
Data sharing rules	<input type="radio"/>				
Data protection rules	<input type="radio"/>				
Product-types structure	<input type="radio"/>				

### Question 3

Has the Biocidal Products Regulation achieved the following objectives related to the functioning of the internal market for biocidal products?

	Fully	To a large extent	To some extent	To a small extent	Not at all	Don't know
Remove obstacles to free circulation of biocidal products and articles treated with them	<input type="radio"/>					
Ensure equal treatment of companies by establishing a level playing field, especially for SMEs and avoid creating monopolies	<input type="radio"/>					
Provide legal certainty	<input type="radio"/>					
Avoid unnecessary burdens for applicants and authorities	<input type="radio"/>					
Ensure effective coordination and harmonisation of actual implementation of rules by Member States (Biocidal Products Committee, Coordination Group, Standing Committee on Biocidal Products, meeting of representatives of Members States competent authorities for the implementation of the Biocidal Products Regulation)						
Ensure compliance with the requirements	<input type="radio"/>					
Ensure a certain level playing field between treated articles manufactured in the EU and treated articles that have been imported into the EU	<input type="radio"/>					

### Question 4

Has the Biocidal Products Regulation achieved its objectives related to ensuring a high level of protection of human and animal health and the environment?

	Fully	To a large extent	To some extent	To a small extent	Not at all	Don't know
Ensure that only safe active substances are used in biocidal products	<input type="radio"/>					
Ban or restrict the use of active substances with the worst hazard profile	<input type="radio"/>					

Ensure that biocidal products cannot be made available on the market unless authorised	<input type="radio"/>					
Encourage use of less hazardous products	<input type="radio"/>					
Encourage the development of new active substances on the market	<input type="radio"/>					
Ensure availability of biocidal products if needed to combat a serious danger for public health /environment or protect the cultural heritage	<input type="radio"/>					
Ensure appropriate enforcement of the rules	<input type="radio"/>					
Minimise animal testing	<input type="radio"/>					
Encourage sustainable use of biocidal products	<input type="radio"/>					
Ensure that only safe articles treated with biocides are placed on the EU market	<input type="radio"/>					
Ensure that adequate and necessary information on the risks and precautions for use is conveyed to the user	<input type="radio"/>					

## Question 5

Has the implementation of the Biocidal Products Regulation been effective?

	Very effective	Effective	Ineffective	Very ineffective	Don't know
Review programme to review the safety and efficacy of all existing biocidal active substances	<input type="radio"/>				
Exclusion and substitution criteria. Rules for products containing substances meeting these criteria, including comparative assessment	<input type="radio"/>				
Analysis of alternatives	<input type="radio"/>				
Simplified authorisation procedure	<input type="radio"/>				
Same biocidal products	<input type="radio"/>				
Biocidal product families	<input type="radio"/>				
National authorisation of biocidal products /renewals	<input type="radio"/>				
Mutual recognition of national authorisations /renewals	<input type="radio"/>				

Parallel trade permits	<input type="radio"/>				
Derogations from the requirements	<input type="radio"/>				
Labelling requirements	<input type="radio"/>				
Data sharing rules	<input type="radio"/>				
Data protection rules	<input type="radio"/>				

## Question 6

What factors supported or hindered implementation and how do these factors relate to the EU intervention? You should provide examples and be specific

1500 character(s) maximum

## Question 7

What is the contribution of the exclusion criteria for decision-making on active substances to the following objectives?

	Highly positive	Positive	No effect	Negative	Highly negative	Don't know
Protection of human health	<input type="radio"/>					
Protection of animal health	<input type="radio"/>					
Protection of the environment	<input type="radio"/>					
Reduced animal testing	<input type="radio"/>					
Functioning of the internal market	<input type="radio"/>					

## Question 8

What is the contribution of the substitution criteria for decision-making on active substances to the following objectives?

	Highly positive	Positive	No effect	Negative	Highly negative	Don't know
Protection of human health	<input type="radio"/>					
Protection of animal health	<input type="radio"/>					
Protection of the environment	<input type="radio"/>					

Reduced animal testing	<input type="radio"/>					
Functioning of the internal market	<input type="radio"/>					

## Question 9

How would you qualify the following criteria for the approval of active substances?

	Very lenient	Somewhat lenient	Appropriate	Somewhat strict	Very strict	Don't know
Exclusion criteria	<input type="radio"/>					
Substitution criteria	<input type="radio"/>					
Criteria for eligibility for Annex I inclusion	<input type="radio"/>					
Other approval criteria (i.e. for substances not in Annex I, substances not fulfilling exclusion criteria, substances that are not candidates for substitution)	<input type="radio"/>					

## Question 10

Are factors other than environmental and human health related, like social and economic factors, sufficiently taken into account in the decision-making for active substances approval?

	Fully	Sufficiently	Insufficiently	Highly insufficiently	Don't know
Social factors	<input type="radio"/>				
Economic factors	<input type="radio"/>				
Other factors (please specify)	<input type="radio"/>				

## Question 11

A specific objective of the Biocidal Products Regulation is to facilitate substitution of the most hazardous substances with other substances or by alternative methods. Do you think the current rules support the substitution of most/more hazardous biocidal active substances or products?



Completely

- To a large extent
- To a limited extent
- Not at all
- Don't know

### **Question 12**

How has the implementation of the Biocidal Products Regulation affected the availability of biocidal products in your country?

- Drop in availability
- Rise in availability
- No change
- Don't know

### **Question 13**

If you experienced a decline in the availability of certain biocidal products, do you think that the products/methods available can still effectively control harmful organisms?

*1000 character(s) maximum*

### **Question 14**

How has the implementation of the Biocidal Products Regulation affected the prices of biocidal products in your country?

- Prices fell
- Prices rose
- No change
- Don't know

### **Question 15**

Have any external factors (technological progress, global challenges, other legislation) influenced the effectiveness of the Biocidal Products Regulation? If yes, how?

*1000 character(s) maximum*

**Evaluation criterion: EFFICIENCY (Are the costs of the Biocidal Products Regulation justified in view of its benefits?)**

**Question 16**

Are the legal timelines set out in the Biocidal Products Regulation adequate?

	Should be decreased	Are adequate	Should be increased	Don't know
Active substance approval	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Active substance renewal	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Simplified authorisation procedure	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Same biocidal products authorisation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
National authorisation of biocidal products /product families	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Renewal of national authorisation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Mutual recognition in parallel	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Mutual recognition in sequence	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Renewal of authorisations granted by mutual recognition	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Union authorisation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Renewal of Union authorisations	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**Question 17**

How efficient are the current procedures in relation to the benefits and effects achieved? You should consider the costs incurred by the actors involved (industry, regulatory authorities, consumers).

	Very efficient	Efficient	Inefficient	Very inefficient	Don't know
Review programme	<input type="radio"/>				
Approval of new active substances	<input type="radio"/>				
Active substance renewal	<input type="radio"/>				
Early review of an active substance approval	<input type="radio"/>				

Analysis of alternatives	<input type="radio"/>				
Simplified authorisation procedure	<input type="radio"/>				
Same biocidal products	<input type="radio"/>				
Biocidal products families	<input type="radio"/>				
Inclusion of in-situ products within the scope	<input type="radio"/>				
National authorisation of biocidal products /renewals	<input type="radio"/>				
Mutual recognition of national authorisations /renewals	<input type="radio"/>				
Union authorisations/renewals	<input type="radio"/>				
Parallel trade permits	<input type="radio"/>				
Rules for treated articles	<input type="radio"/>				
Derogations from the requirements	<input type="radio"/>				
Labelling requirements	<input type="radio"/>				
Data sharing rules	<input type="radio"/>				
Data protection rules	<input type="radio"/>				
Transitional provisions, including Article 95 list	<input type="radio"/>				
Data requirements for active substance approval	<input type="radio"/>				
Data requirements for product authorisation	<input type="radio"/>				
Product type structure	<input type="radio"/>				

### Question 17.a.

Is there potential for rules or reporting simplification and/or burden reduction?

*Give examples and be as precise as possible.*

1500 character(s) maximum

## Question 18

What benefits have you experienced as a result of the implementation of the Biocidal Products Regulation?

*Give examples and be as precise as possible.*

*1500 character(s) maximum*

## Question 19

Have the Biocidal Products Regulation's rules and procedures improved the product authorisation process?

- Fully
- To a large extent
- To some extent
- To a small extent only
- Not at all
- Don't know

## Question 20

What are the biggest challenges or bottlenecks you have encountered in the product authorisation process?

*1500 character(s) maximum*

## Question 21

Do you think that the Biocidal Products Regulation has contributed to the competitiveness of the biocides sector?

*1500 character(s) maximum*

## Question 22

Do you think the Biocidal Products Regulation has contributed to innovation in the biocides sector?

*1500 character(s) maximum*

## Question 23

What are the most important barriers to competitiveness and innovation in this sector?

*1500 character(s) maximum*

## Question 24

What are the most important barriers to creating a level playing field for all economic operators (regardless of size or market position)?

*1500 character(s) maximum*

## Question 25

How would you simplify the product authorisation process?

*1500 character(s) maximum*

**Evaluation criterion: RELEVANCE (Does the Biocidal Products Regulation address current and upcoming challenges?)**

## Question 26

Is the Biocidal Products Regulation fit for purpose?

- Yes
- No
- Don't know

## Question 27

Is the scope of the Biocidal Products Regulation still relevant?

- Highly relevant
- Somehow relevant
- Relevant
- Irrelevant
- Don't know

## Question 28

Are the following requirements/criteria still relevant in the light of latest technical and scientific developments?

	Still relevant	Need modification	Don't know
Criteria for active substance approval	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Data requirements for active substance approval	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Conditions for authorisation of biocidal products	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Data requirements for authorisation of biocidal product	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Data sharing rules	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rules for placing on the market of treated articles	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

## Question 29

To what extent do existing provisions allow enough flexibility to consider new scientific information (for instance, new toxicological information)?

- Fully
- To a large extent
- To some extent
- To a small extent only
- Don't know

## Question 30

Do the rules allow enough flexibility to consider new scientific information, like new toxicological information?

- Fully
- To a large extent
- To some extent
- To a small extent only
- Don't know

## Question 31

How transparent are the processes for approving active substances?

--	--	--	--	--	--	--	--

	Fully	To a large extent	To some extent	To a small extent	Not at all	Don't know
Risk assessment by evaluating competent authority	<input checked="" type="radio"/>					
Peer-review by Biocidal Product Committee	<input checked="" type="radio"/>					
Risk management by the European Commission	<input checked="" type="radio"/>					

## Question 32

How transparent are the processes for authorising biocidal products?

	Not at all	To a small extent	To some extent	To a large extent	Fully	Don't know
Risk assessment by evaluating competent authority	<input checked="" type="radio"/>					
Resolving disagreements in mutual recognition procedures in the Coordination Group	<input checked="" type="radio"/>					
Authorisation decision by Member States or the European Commission	<input checked="" type="radio"/>					

## Question 33

How would you improve transparency?

1500 character(s) maximum

**Evaluation criterion: COHERENCE (Is the Biocidal Products Regulation consistent internally and with other related EU and international policies and interventions?)**

## Question 34

Is the Biocidal Products Regulation coherent as a piece of legislation (no contradictions or gaps in its provisions)?

- To a large extent
- To some extent
- To a small extent
-

Not at all  
 Don't know

### Question 35

Is the Biocidal Products Regulation coherent with the following EU public health and environmental legislation?

	To a great extent	To some extent	To a small extent	Not at all	Don't know
Regulation (EC) No 1907/2006 (REACH Regulation)	<input checked="" type="radio"/>				
Regulation (EC) No 1272/2008 (Classification, Labelling and Packaging of Substances and Mixtures Regulation)	<input checked="" type="radio"/>				
Regulation (EC) No 1107/2009 (Plant Protection Products Regulation)	<input checked="" type="radio"/>				
Regulation (EC) No 1935/2004 (Food Contact Materials Regulation)	<input checked="" type="radio"/>				
Regulation (EC) No 1223/2009 (Cosmetics Regulation)	<input checked="" type="radio"/>				
Regulation (EC) No 648/2004 (Detergents Regulation)	<input checked="" type="radio"/>				
Regulation (EU) 2019/6 (Veterinary Medicines Regulation)	<input checked="" type="radio"/>				

### Question 36

Is the Biocidal Products Regulation coherent with the following international policies /conventions?

	To a great extent	To some extent	To a small extent	Not at all	Don't know
Rotterdam Convention on the prior informed consent procedure for certain hazardous chemicals and pesticides in international trade	<input checked="" type="radio"/>				
Stockholm Convention on Persistent Organic Pollutants	<input checked="" type="radio"/>				
International Convention on the Control of Harmful Anti-fouling Systems on Ships	<input checked="" type="radio"/>				
UN Global Framework on Chemicals	<input checked="" type="radio"/>				
OECD legal instruments concerning chemicals	<input checked="" type="radio"/>				

## Question 37

Are there any inconsistencies in the Biocidal Products Regulation?

*Briefly describe them providing examples.*

1000 character(s) maximum

**Evaluation criterion: EU ADDED VALUE (Does the Biocidal Products Regulation provide benefits that could not be achieved at the national level alone?)**

## Question 38

Has the Biocidal Products Regulation been beneficial regarding the objectives pursued that could not have been achieved by Member States alone?

- Yes
- No
- Don't know

## Question 39

At which level of governance should biocidal products be regulated?

- EU level
- National level
- Both EU and national level
- Don't know

## Question 40

The risk assessment process to approve active substances involves authorities at national and EU level. At which level should this process be handled?

- National level
- EU level
- Current system (both national and EU level)
- Both national and EU level, but different than current system
- Don't know

## Question 41

The risk assessment process for Union authorisation of products involves authorities at national and EU level. At which level should this process be handled?

- National level
- EU level
- Current system (both national and EU level)
- Both national and EU level, but different than current system
- Don't know

## Question 42

What would be the most likely consequence of not having an EU biocidal products legislation?

*1500 character(s) maximum*

### Additional information

You can provide further information.

*2500 character(s) maximum*

You can upload a concise document, such as additional evidence supporting your answers or a position paper.

Uploaded documents will be published on 'Have your say' alongside your answers to the questionnaire.

Only files of the type pdf,txt,doc,docx,odt,rtf are allowed

## Contact

[SANTE-BIOCIDES@ec.europa.eu](mailto:SANTE-BIOCIDES@ec.europa.eu)

